Skip to main
SRZN

Surrozen (SRZN) Stock Forecast & Price Target

Surrozen (SRZN) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Surrozen is a clinical-stage biotechnology company with a positive outlook as evidenced by strong financials including $106.9 million in cash and equivalents as of March 2026, and a net loss of $127.5 million for 1Q26. With their product candidates SZN-8141, SZN-413, and SZN-8143 targeting Wnt pathway mediation in a variety of retinal diseases, Surrozen has the potential to provide important innovations and address unmet needs in the retinal disease space. Risks to their investment thesis and target price include failure to commercialize their developmental candidates and secure capital resources, but their advancements in the retinal therapeutic space and potential for earlier therapeutic use make them a strong contender in the market.

Bears say

Surrozen is a clinical-stage biotech company with a focus on developing novel therapeutics in severe eye diseases and other organs, using the Wnt signaling pathway. However, the company is still in the early stages of development and faces risks such as failure to achieve peak commercial revenue estimates and secure sufficient funding. Additionally, the success of their lead candidate SZN-8141 may be impacted by unexpected toxicities or competing studies. Based on these factors, the future success and growth of Surrozen is uncertain, leading to a negative outlook on the stock.

Surrozen (SRZN) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Surrozen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Surrozen (SRZN) Forecast

Analysts have given Surrozen (SRZN) a Buy based on their latest research and market trends.

According to 2 analysts, Surrozen (SRZN) has a Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $42, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $42, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Surrozen (SRZN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.